Skip to main content
TipRanks
Go Ultimate75% OFF

Agios Pharma (0HB0) Share Price & Analysis

0 Followers

0HB0 Stock Chart & Stats

$29.54-$1.02(-3.34%)
At close: 4:30 PM GMT
$30$32.5$35$37.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$29.54 - $30.56
52-Week Range
$22.40 - $45.81
Previous Close
$30.56
Volume
N/A
Average Volume (3M)
489
Market Cap
$1.79B
Enterprise Value
$1.38B
Total Cash (Recent Filing)
$630.01M
Total Debt (Recent Filing)
$26.53M
Price to Earnings (P/E)
―
Beta
1.70
Next Earnings
Feb 25, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Commercial Revenue Growth

The sharp increase in quarterly revenue shows meaningful commercial traction for AQVESME and expanding product adoption. If prescription growth and persistence continue, the launch can create a stronger recurring revenue base and improve operating leverage over the next several quarters.

Strong Product Persistence And Market Access

High patient persistence supports recurring product revenue and suggests the therapy is delivering durable value after initiation. Broad payer coverage also reduces access friction, helping the company convert prescriptions into sustained treatment and supporting longer-term launch economics.

Financial Flexibility From Cash And Low Leverage

A substantial cash reserve combined with minimal leverage gives Agios capacity to fund commercial expansion, clinical development, and potential launches without near-term dependence on heavy borrowing. This financial flexibility supports execution while management works toward profitability.

Bears Say

Persistent Losses And Cash Burn

Large ongoing losses and negative free cash flow mean the business is not yet self-funding despite accelerating revenue. Continued cash consumption could reduce financial flexibility over time and may require operating improvement or additional financing before profitability is reached.

Regulatory Uncertainty For Sickle Cell Launch

The extended FDA review delays potential sickle cell commercialization and leaves launch timing dependent on additional regulatory work. A required REMS could also add prescribing, education, or monitoring requirements, potentially increasing adoption friction and launch costs.

Elevated Commercial Operating Expenses

Higher selling and administrative spending is placing pressure on near-term profitability as Agios builds commercial infrastructure and supports multiple launches. Revenue growth will need to outpace these costs for the company to achieve sustainable operating leverage and its profitability target.

Agios Pharma News

0HB0 FAQ

What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest share price was $22.40 and its highest was $45.81 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.79B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 99 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Nov 05, 2026. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.244 by $0.154.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Agios Pharma dividends here
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.11.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,809,650 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.244. Following the earnings report the stock price went down -9.398%.
Which hedge fund is a major shareholder of Agios Pharma?
Hedge funds hold Agios Pharma shares: the largest hedge-fund position in Agios Pharma is 105,563,203 shares, and hedge funds increased their holdings by 159.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology